Key facts
- This page summarizes Eric Shroff's Form 3 filing for ABBOTT LABORATORIES (ABT).
- 0 reported transactions and 7 derivative rows are listed below.
- Accepted by SEC: 03 Mar 2025, 20:29.
Eric Shroff - 01 Mar 2025 Form 3 Insider Report for ABBOTT LABORATORIES (ABT)
- Reporting relationship
- Senior Vice President
- Issuer ticker
- ABT
- Reported as of
- 01 Mar 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 03 Mar 2025, 20:29:56 UTC
- Next SEC filing
- 04 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Eric Shroff by Jessica H. Paik, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Eric Shroff filed Form 3 for ABBOTT LABORATORIES (ABT) on 03 Mar 2025.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ABT
holding
Common shares without par value
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 32,532
- Date
- 01 Mar 2025
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ABT
holding
Derivative
Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 26,971
- Exercise price
- $75.90
ABT
holding
Derivative
Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 29,020
- Exercise price
- $87.72
ABT
holding
Derivative
Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Mar 2025
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 20,045
- Exercise price
- $124.04
ABT
holding
Derivative
Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Mar 2025
- Ownership
- Direct
- Underlying class
- Common shares
- Underlying amount
- 20,404
- Exercise price
- $117.58
ABT
holding
Derivative
Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Mar 2025
- Ownership
- Direct
- Underlying class
- Common shares
- Underlying amount
- 13,056
- Exercise price
- $106.24
- Footnotes
- F1
ABT
holding
Derivative
Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Mar 2025
- Ownership
- Direct
- Underlying class
- Common shares
- Underlying amount
- 13,250
- Exercise price
- $116.98
- Footnotes
- F2
ABT
holding
Derivative
Option (right to buy)
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- Date
- 01 Mar 2025
- Ownership
- Direct
- Underlying class
- Common shares
- Underlying amount
- 27,227
- Exercise price
- $135.42
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,352 on February 17, 2024, 4,352 on February 17, 2025, and 4,352 on February 17, 2026.
Footnote F2
Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,416 on February 21, 2025, 4,417 on February 21, 2026, and 4,417 on February 21, 2027.
Footnote F3
Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 9,075 on February 25, 2026, 9,076 on February 25, 2027, and 9,076 on February 25, 2028.